A core component of our partnering strategy is to license pipeline product candidates and then further characterize, in concert with our core development strategies, through grants and collaborations with expert researchers and academic centers of excellence.
In July 2016, Cerecor announced that it had been awarded a grant from the National Institute on Drug Abuse (NIDA) at the National Institutes of Health. The grant of approximately $1.0 million provided Cerecor with additional resources for the Phase 2 clinical trial of CERC-501, “A Randomized, Double-Blind, Placebo-Controlled, Crossover Design Study of CERC-501 in a Human Laboratory Model of Smoking Behavior,” which was completed in December 2016.
In April 2016, Cerecor announced that it had been awarded a grant from the National Institute on Alcohol Abuse and Alcoholism (NIAAA) at the National Institutes of Health (NIH). The grant of $1.0 million provides Cerecor with additional resources to progress the development of CERC-501 for the treatment of alcohol use disorder (AUD). Upon successful completion of the development activities covered under this grant, Cerecor will have the opportunity to apply for continued funding.
In July 2016, Cerecor announced that the Pharmacotherapies for Alcohol and Substance Use Disorders (PASA) Consortium had provided a grant of nearly $0.2million Cerecor and investigators from the University of Houston. The PASA Consortium is funded by the Department of Defense Congressionally Directed Medical Research Programs as part of its Alcohol and Substance Abuse Research Program. The PASA Consortium goal is funding study applications for developing new medications that can be brought to therapeutic use to improve treatment outcomes for alcohol and substance use disorders, especially as related to PTSD.
Contact us to learn more about partnership opportunities.